Financial Performance - The company's revenue increased by 18.4% year-over-year, reaching RMB 13318 million in 1H 2025[4] - Net profit increased significantly by 63.1% year-over-year to RMB 876 million in 1H 2025[4] - Basic EPS increased by 65.2% year-over-year to RMB 0.76 in 1H 2025[4] - Operating cash inflow increased by 9.1% year-over-year to RMB 2.89 billion, with free cash flow at RMB 1.86 billion[8] Segment Performance - Acoustics business revenue increased by 1.8% year-over-year to RMB 3.52 billion in 1H 2025, representing 26% of total revenue[13, 12] - Automotive acoustics business revenue increased by 14.2% year-over-year to RMB 1.74 billion in 1H 2025, accounting for 13% of total revenue[18, 17] - Optics business revenue increased by 19.7% year-over-year to RMB 2.65 billion in 1H 2025, contributing 20% of total revenue[22, 21] - Electromagnetic Drives and Precision Mechanics revenue increased by 27.4% year-over-year to RMB 4.63 billion in 1H 2025, making up 35% of total revenue[26, 25] - Sensor and Semiconductor business revenue increased significantly by 56.2% year-over-year to RMB 608 million in 1H 2025, representing 5% of total revenue[35, 34] Optics Gross Margin Improvement - Optics gross margin significantly improved by 5.5 percentage points year-over-year, reaching 10.2% in 1H 2025[22]

東方海外（國際）有限公司 2025 Interim Results | 2025 年中期業績 2 (1) The information/contents herein includes both data provided from Orient Overseas (International) Limited ("OOIL") and its affiliates and data obtained from relevant third-party information provider(s). Such information/contents is purely intended for your reference only and is subject to changes/updates at any time without further notice. (2) The information/contents herein is not a recommendation, an offer to buy, sell or trade in nor solicitation of an ...

Financial Performance - The company's revenue increased by 3.4% from RMB 74,412 million in 1H2024 to RMB 76,939 million in 1H2025 [8] - Net profit saw a slight increase of 0.2%, rising from RMB 2,125 million in 1H2024 to RMB 2,129 million in 1H2025 [8] - Gross profit decreased by 2.8% from RMB 8,116 million to RMB 7,888 million [8] - Operating profit increased by 6.3% from RMB 1,481 million in 1H2023 to RMB 1,706 million in 1H2025 [12] - SG&A expenses decreased by 5.5% from RMB 6,542 million to RMB 6,182 million [86] Business Segments - Telecommunications Infrastructure Services (TIS) revenue increased by 1.6%, from RMB 37,666 million in 1H2024 to RMB 38,272 million in 1H2025 [15] - Business Process Outsourcing (BPO) services revenue increased by 1.0%, from RMB 22,163 million in 1H2024 to RMB 22,383 million in 1H2025 [15] - Applications, Content and Other Services (ACO) revenue increased significantly by 11.7%, from RMB 14,583 million in 1H2024 to RMB 16,284 million in 1H2025 [15] Market Performance - Domestic Non-operator market revenue increased by 12.9% [15] - Overseas market revenue increased by 8.7% [15] - Domestic Operator market revenue decreased by 4.6% [15] Strategic Initiatives - New contracts of strategic emerging businesses in 1H2025 exceeded RMB 42 billion, representing an increase of over 10% year-on-year [26] - Digital infrastructure new contracts increased by over 20% [30] - Smart city new contracts increased by over 15% [34]

Financial Performance - Total revenues and other income increased by 6% to US$1242 million in 1H 2025 [12] - Core lease rental contribution increased by 24% to US$342 million in 1H 2025 [12] - Core net profit after tax increased by 20% to US$342 million in 1H 2025 [12] - Operating cash flow net of interest reached US$1 billion in 1H 2025 [67] Balance Sheet and Portfolio - Total assets increased by 2% to US$256 billion as of June 30, 2025 [13] - Total equity increased by 2% to US$65 billion as of June 30, 2025 [13] - Total liquidity was US$61 billion as of June 30, 2025 [13] - The company's portfolio exceeded 830 aircraft and engines [31] Dividends and Lease Terms - The 2025 interim dividend per share is US$01476, the second highest on record [16] - The average remaining lease term is 79 years [47] Future Growth - The company has a record total future committed capex of US$20 billion [82]

Financial Performance - Revenue decreased by 9.87% from RMB 26,471.527 million in 1H2024 to RMB 23,857.644 million in 1H2025[12] - Fuel costs decreased by 26.16% from RMB -7,922.234 million in 1H2024 to RMB -5,849.834 million in 1H2025[12] - Depreciation increased by 11.29% from RMB -6,070.658 million in 1H2024 to RMB -6,755.962 million in 1H2025[12] - Operating profit increased by 1.94% from RMB 7,466.308 million in 1H2024 to RMB 7,611.019 million in 1H2025[12] - Profit attributable to equity holders of the company increased by 1.16% from RMB 2,802.197 million in 1H2024 to RMB 2,834.655 million in 1H2025[12] - Total assets increased by 3.60% from RMB 340,455.547 million on 2024.12.31 to RMB 352,714.191 million on 2025.06.30[13] - Total liabilities increased by 2.96% from RMB 232,923.154 million on 2024.12.31 to RMB 239,821.682 million on 2025.06.30[13] Operational Data - The ratio of clean energy revenue increased from 60.29% in 1H2024 to 64.20% in 1H2025[23] - Consolidated capacity increased by 6.99% from 39,869.7 MW on 2024.6.30 to 42,658.8 MW on 2025.6.30[25] - Net power generation decreased by 2.8% from 64,344 GWh in 1H2024 to 62,537 GWh in 1H2025[31]

ck Code : 1093) 2025 Interim Results Presentation Aug. 2025 ININI China's Leading Innovative Pharmaceutical Enterprise R&D Capabilities 00 5 capacity of 250,000L R&D centers located in R&D platforms China & the U.S. 201010 + - 2401 Innovative drugs and R&D professionals new formulations Manufacturing Capabilities Commercialization Capabilities 2 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation Chemical drugs production capacity o ...

2025 First Half Investor Presentation A u g 2 0 2 5 Legal Disclaimer 2 • This document has been prepared by YEAHKA LIMITED (the "Company" or "us") for a limited number of recipients and for information purposes only and not for public dissemination. You and your directors, officers, employees, agents and affiliates must hold this document and any oral information provided in connection with this document in strict confidence and may not communicate, reproduce, distribute or disclose it to any other person, ...

Financial Performance Highlights - VONB increased by 14% to $2,838 million[11], driven by broad-based growth across 13 markets[49] - OPAT per share increased by 12%[11], reflecting higher earnings and ROE[41] - UFSG per share increased by 10% to $3,569 million[11] - Interim dividend per share increased by 10% to 49.00 HK cents[47] - $3.7 billion was returned to shareholders[13] Key Growth Drivers - AIA Hong Kong's VONB grew by 24% to $1,063 million[15], supported by agency and bancassurance channels[15] - AIA China's VONB reached $743 million in 1H25[17], with a VONB margin exceeding 65%[17] - ASEAN combined VONB increased by 20%[22], driven by traditional protection products[22] - Tata AIA Life's VONB increased by 38%[25], positioning it as a top 3 private life insurer in India[25] Strategic Initiatives - The company is deploying Gen AI at scale to accelerate growth across core platforms[38] - The company is focused on integrated healthcare strategy to make healthcare more accessible, affordable, and effective[35] - The company is building a differentiated and sustainable bancassurance model in China, focusing on HNW customers[104] Capital Management - The company maintains a strong shareholder capital ratio of 219% after returning $3.7 billion to shareholders[47, 82] - The company has a disciplined capital deployment strategy, with $22 billion returned since 2022[81] - The company targets a payout ratio of 75% of annual net free surplus generation[75]

Financial Performance - Revenue increased by 16.1% year-over-year to RMB 10 billion[7], with adjusted EBITDA up 20.6% to RMB 4.3 billion[7] and adjusted net profit up 11.6% to RMB 2.8 billion[7] - Gross profit margin improved by 360 basis points to 42.7%[7], with adjusted EBITDA margin at 43.3% and adjusted net profit margin at 28.5%[7] - Basic earnings per share (EPS) increased by 56.8% to RMB 0.58[7] Business Growth and Backlog - Integrated projects increased by 16.4% year-over-year to 864[8] with 86 new projects added in 1H 2025[9] - Commercial projects increased by 50% year-over-year to 24[9] - Total backlog reached US$20.3 billion[9, 16], including US$11.4 billion in service backlog[17] and US$4.2 billion within 3 years[17] Revenue Breakdown and Geography - Pre-IND revenue rose 35.2% year-over-year in 1H 2025[11] - Late-stage + CMO revenue increased by 24.9% year-over-year[12] - North America revenue grew 20.1% year-over-year, accounting for 60.5% of total revenue[21, 22] Capacity and Quality - The company completed 44 regulatory inspections with a 100% success rate[9, 66] - The company has 16 drug substance facilities and DP facilities with ~500,000L bioreactor capacity[51] Technology and Innovation - The company has enabled 50+ programs with potential milestone & sales royalty[13, 40] - The company is scaling out single-use technology to large batch sizes, with 339 batches across 5 manufacturing facilities[99] WBS and ESG - The company is improving gross margin through WBS initiatives[105] - The company is committed to sustainability and has received several ESG ratings and awards[108]

1 Disclaimer ◼These materials have been prepared by China State Construction International Holdings Ltd. ("CSCI" or the "Company") solely for information use during its presentation. It may not be reproduced or redistributed to any other person without the permissions from CSCI. By attending this presentation, you are agreeing to be bound by the foregoing restrictions. ◼It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the compa ...